Propylex

Quick links to important sections

Propylex

Method of action: Antithyroid, Thyroid Therapy

Treatment option: Hyperthyroidism, Thyrotoxicosis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Propylex

Property Description
Active ingredient Propylthiouracil (PTU)
Form Oral Tablet
Pharmacological class Thioamide Antithyroid Agent
Common use Management of Hyperthyroidism
Origin Synthetic Compound

What Type of Medicine is Propylex?

Propylex is a prescription-only medicine containing the active component Propylthiouracil (PTU), which is medically classified as a thioamide antithyroid agent. This classification places it within the group of pharmaceuticals specifically designed to modulate the function of the thyroid gland. As a synthetic compound derived from thiourea, it is not of natural origin and is provided as a single active ingredient product, typically formulated as an oral tablet for oral route administration.

What is Propylthiouracil's General Therapeutic Purpose?

The high-level therapeutic use of Propylthiouracil is the fundamental management of conditions characterized by an overactive thyroid, medically termed hyperthyroidism. The purpose of this medication is to interrupt the underlying pathology causing the hormonal imbalance, rather than treating the symptoms directly. The pharmacological use of Propylthiouracil is confirmed in its role in managing hyperthyroidism by inhibiting the thyroid gland's ability to produce hormones. This essential regulatory function serves to lower the body's accelerated metabolism and transition the patient toward a state of hormonal balance, known as a euthyroid state.

How Does Propylthiouracil Fundamentally Affect Hormones?

Propylthiouracil is fundamentally a thyroid hormone synthesis inhibitor that works by limiting the production and activation of key thyroid hormones, thyroxine (T4) and triiodothyronine (T3). This mechanism of effect operates on two distinct fronts: it reduces the thyroid gland's ability to manufacture new hormones, and, uniquely among many antithyroid agents, it also partially blocks the body’s ability to convert the less potent form of the hormone (T4) into the highly active form (T3) in peripheral tissues. This combined action achieves a rapid and substantial reduction of thyroid hormone levels in the bloodstream.

Regulatory References

  1. Propylthiouracil - LiverTox - NCBI Bookshelf
  2. Propylthiouracil Drug Information

What side effects are possible with Propylex?

Possible Side Effects and Safety Information

Propylex (Propylthiouracil) is associated with adverse reactions that are classified by frequency and grouped according to the affected physiological system, as documented in official regulatory sources like the FDA and EMA. The safety profile is structured around potential risks to the blood system and the liver, requiring explicit communication of specific safety constraints.


Official Adverse Reaction Scope

Adverse reactions are classified according to incidence. Common reactions (e.g., geq 1/100) include joint pain (Arthralgia), itching (Pruritus), and Urticaria (hives). Serious adverse reactions are formally documented, including potentially life-threatening conditions such as Agranulocytosis (a severe drop in white blood cells), which typically occurs within the initial three months of treatment, and Severe Hepatotoxicity leading to Acute Liver Failure.


Systemic and Time-Related Safety Patterns

The primary System-Organ Classes involved are Hepatobiliary Disorders and Blood and Lymphatic System Disorders. Less common but severe reactions include ANCA-associated Vasculitis, which can affect multiple organs and may appear with prolonged use. The risk of Hepatotoxicity is often reported within the first six months of therapy. The medicine is contraindicated in individuals with a history of hypersensitivity to the drug and in those with pre-existing severe hepatic impairment.


Population-Specific Safety Constraints

Official regulatory texts note specific safety constraints for vulnerable populations. Pediatric patients have been associated with an increased risk of severe hepatotoxicity and acute liver failure. For pregnant patients, Propylthiouracil is administered at the lowest effective dose due to the documented risk of causing fetal goiter and cretinism. Treatment can induce Hypothyroidism, necessitating formal monitoring of thyroid hormone levels to maintain a euthyroid state.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Propylthiouracil (Propylex) is defined in regulatory documents based on specific clinical signs and required emergency actions. Immediate medical attention is required if overdose is suspected.

Documented Overdose Presentations

Overdose may manifest with gastrointestinal symptoms such as Nausea, Vomiting, and Epigastric distress. Other documented signs include Headache, Fever, Arthralgia (joint pain), Edema (swelling), and Pruritus (itching). Repeated over dosage is known to induce long-term endocrine effects, specifically the development of Goitre and Hypothyroidism.

Serious Outcomes and Emergency Action

The regulatory labels classify certain outcomes as severe. Agranulocytosis is noted as the most serious hematological effect, alongside Pancytopenia. Rarely, Hepatitis or Exfoliative dermatitis may occur. Users must immediately contact emergency services if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Immediate medical evaluation is necessary for signs of serious toxicity, such as fever, sore throat, or jaundice.

Management and Monitoring

There is no specific antidote for Propylthiouracil overdose documented in official labeling. Management focuses on minimizing drug absorption through procedures such as gastric lavage or the use of activated charcoal, followed by general symptomatic and supportive measures. Due to the risk of blood abnormalities, a full blood analysis must be considered for monitoring purposes.

Therapeutic Uses of Propylex

What Propylex Treats: Main Uses and Benefits

Propylex (Propylthiouracil) is a specialized treatment commonly used to help manage symptoms related to systemic imbalance, focusing on the conditions treated and the practical benefits derived from supporting hormonal balance. The medication is applied in addressing symptoms related to heightened physiological activity.


Core Therapeutic Focus

This medication is fundamentally used for managing conditions characterized by an overactive thyroid (hyperthyroidism). This includes its primary causes, such as Graves' disease and toxic multinodular goiter. The treatment is also relevant for easing symptoms associated with acute or disruptive episodes, such as thyroid storm or thyrotoxic crisis, and is commonly used in clinical settings as a pretreatment regimen to support the maintenance of hormonal stability before proceeding with definitive therapies like thyroidectomy or radioactive iodine therapy.

The core therapeutic benefit provided may assist with achieving a stable euthyroid state by managing the excessive levels of thyroid hormones in the bloodstream. By controlling the resulting accelerated metabolic rate, Propylex helps improve patient comfort and functional stability, is used for managing the strain associated with an overly rapid heart rate, tremors, and severe heat intolerance.

“The medication plays a role in helping patients cope more steadily with symptom fluctuations associated with thyroid overactivity.”


Symptomatic Support Focus Propylex provides supportive relief that helps ease the overall symptom burden associated with an accelerated heart rate and heat intolerance, contributing to improved comfort during symptomatic periods.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Propylex

Propylex (Propylthiouracil) eligibility rules are defined by regulatory authorities and govern which patient populations are permitted, restricted, or prohibited from receiving the medicine.


Eligibility Scope

Category Regulatory Status
Populations for whom use is contraindicated Patients with known hypersensitivity to the drug or its excipients, or a history of previous severe reactions, including agranulocytosis or hepatitis.
Populations for whom use is not recommended Children under 6 years of age. Use in the general pediatric population is generally not recommended.
Age-related eligibility rules Adults are eligible for standard use. Older adults require caution due to potential co-morbidities.
Condition-specific eligibility rules Use requires caution in patients with renal impairment or hepatic disease.
Pregnancy and lactation eligibility Use is permitted at the lowest effective dose, and may be preferred during the first trimester. Breastfeeding is generally not precluded.

Eligibility-Related Restrictions

Propylthiouracil is designated as a reserved treatment option for adult and pediatric patients. Eligibility is strictly conditional on the patient being intolerant of Methimazole and for whom definitive therapies, such as surgery or radioactive iodine, are not considered appropriate options. Caution is also advised for patients with myelosuppression.

What should I know about interactions with other medicines?

Propylex Interactions with other medicines and products

Propylex (Propylthiouracil) has documented interaction patterns based on its effect on the thyroid state and its potential for synergistic risk, as outlined in official regulatory documents. All interaction information is presented strictly as stated by regulatory authorities.


Official Interaction Statements

  • Co-administration is contraindicated with Sodium Iodide I-131 (Radioactive Iodine). Propylthiouracil must be discontinued at least 2 to 4 days prior to administration to ensure the therapeutic efficacy of the radio-iodine treatment is not reduced.
  • Propylthiouracil may increase the activity of Oral Anticoagulants, such as Warfarin, due to its potential to inhibit Vitamin K activity, raising the documented risk of hypoprothrombinemia.
  • Concurrent use with other Drugs Known to Cause Agranulocytosis may result in an increased risk of toxicity due to the potential for synergistic bone marrow suppression.
  • The patient's conversion from a hyperthyroid to a euthyroid state is officially documented to affect drug clearance. This change can decrease the clearance of co-administered medicines, including Beta-adrenergic blocking agents and Theophylline.
  • Propylthiouracil clearance is reduced in patients with a reduced Glomerular Filtration Rate (GFR), representing a population-specific pharmacokinetic consideration.
  • No known interactions are documented in the regulatory labeling for Propylthiouracil with food or drinks.

Summary of Interaction Structure

The regulatory profile defines the interaction structure through pharmacodynamic effects (e.g., increased anticoagulant activity) and indirect pharmacokinetic effects. The latter occurs when the achievement of a stable thyroid state alters the clearance of co-administered drugs like beta-blockers. The most critical constraint is the mandatory timing restriction required before radioactive iodine procedures.

Mechanism of Action

Propylex, which is propylthiouracil (PTU), is a thiourea antithyroid agent that accumulates selectively within the thyroid gland.

Its primary molecular target is the enzyme thyroid peroxidase (TPO), with which it interacts as a non-competitive inhibitor. This interaction blocks TPO's catalytic action, which includes the oxidation of iodide (I^-) to active iodine (I^0) and the subsequent iodination of tyrosyl residues on the thyroglobulin protein (organification). This inhibition of iodination and coupling prevents the formation of the thyroxine (T4) and triiodothyronine (T3) precursor molecules.

A secondary interaction type is the non-competitive inhibition of Type I 5'-deiodinase (D1) in peripheral tissues. This enzyme is responsible for the deiodination of T4 to the more metabolically active T3. The combined intracellular consequences are a significant reduction in the synthesis of new thyroid hormones in the gland and a decrease in the peripheral conversion of T4 to T3, resulting in a systemic decrease in circulating T3 and T4 concentrations.

Dosage and Administration Information

How Propylex is Used

Propylex, containing the active ingredient Propylthiouracil, is administered exclusively via the oral route as a tablet. The application of the medicine is structured into distinct phases, requiring adherence to a fixed, long-term dosing regimen.


Standard Dosing and Frequency Patterns

The treatment protocol begins with an elevated initial dose designed to stabilize thyroid function. The common adult starting dose is 300 mg daily, administered in three equally divided doses at approximately eight-hour intervals. For patients with severe presentation, initial daily doses may be increased, potentially up to 900 mg. To sustain a consistent effect at higher intake levels, more frequent administration intervals, such as every four to six hours, may be necessary.

Once a stable hormonal state is attained, the regimen shifts to a maintenance dose, typically 100 mg to 150 mg daily. The total course of therapy for conditions such as Graves' disease often extends over a long duration, generally lasting for 12 to 18 months or more.


Administration Instructions and Adjustments

Propylthiouracil tablets must be swallowed whole and can be taken with or without food. Doses are taken at evenly spaced times to ensure proper action. If a dose is missed, the instruction is to take it as soon as possible, unless it is almost time for the subsequent dose; doses must not be doubled. Dose adjustments are required for certain populations; for example, the dose is reduced for patients with renal impairment, based on the degree of decreased kidney function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Propylex

Propylex (Propylthiouracil, PTU) has been the subject of formal clinical evaluation, primarily through Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews, to understand the research findings resulting from studies of Propylex. The research summarized here is derived from authoritative governmental and peer-reviewed scientific sources.


Evidence for Use in Managing Hyperthyroidism

Research exploring the use of Propylex often uses RCTs to study it alongside other medications in the same class for hyperthyroidism, such as Graves' disease and toxic nodular goiter. These studies primarily focused on objective measures, such as monitoring the shift in thyroid hormone biomarkers towards the healthy, balanced range. Studies monitored outcomes related to physiological strain or stress, seeking to track changes measured in the observed patient populations.

Studies also examined the durability of response after treatment is completed by tracking remission rates. The data show patterns related to the time it took to reach measured hormone targets in groups of adults. What remains unclear is the precise duration of therapy associated with the highest rates of long-term remission for all patients; this finding was mixed across studies.


Evidence for Use as a Pretreatment Strategy

PTU was studied for its use in clinical situations involving acute episodes prior to receiving definitive treatments, such as Radioactive Iodine ( ^131 I) therapy. Evidence derived from settings with varying symptom burdens described that the pretreatment regimen was associated with measured changes in hormone biomarkers prior to the definitive procedure. However, a body of trial evidence reported that using PTU as a pretreatment was associated with a potentially reduced rate of successful outcome when the patient subsequently received ^131 I therapy. The evidence suggests this association was observed in some studies.


Evidence in Specific Patient Populations

Meta-analyses and Epidemiological Cohort Studies have studied the use of Propylex for managing hyperthyroidism in pregnant women, particularly during the first trimester. These studies focused on tracking maternal thyroid hormone stability and monitoring fetal and neonatal thyroid status. While its use has been studied extensively for measuring hormone levels during the first trimester of pregnancy, evidence for Propylex in the pediatric population is limited compared to data available for adults.

Key Studies & References

  1. Propylthiouracil (PTU) - MotherToBaby | Fact Sheets
  2. Propylthiouracil (PTU) - StatPearls - NCBI Bookshelf
  3. The Differential Effects of Propylthiouracil and Methimazole as Graves' Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial

Frequently Asked Questions (FAQ)

Common questions about Propylex (FAQ)


Q: Is Propylex the same as other medicines with similar names?

Official drug safety documents point out that the generic name, Propylthiouracil, has a documented risk of being confused with the name of another medicine, Mercaptopurine (Purinethol). This is a sound-alike/look-alike warning issued to help prevent potential medication errors. Patients are generally advised to verify their medication information with their prescribing professional or pharmacist.


Q: How quickly does Propylex usually start to work?

Studies indicate that significant therapeutic effects may require between 24 and 36 hours to begin. However, achieving a true state of hormonal balance (remission of hyperthyroidism) often requires continuous use for a longer period, sometimes up to four months or more.


Q: How long can I expect the effects of Propylex to last?

Although the substance itself has a short plasma half-life of around one to two hours, its biological effect on the synthesis of new thyroid hormones is sustained. This prolonged effect allows the medication to be administered at regular, evenly spaced intervals, maintaining consistent action throughout the day.


Q: Is it common to feel tired after starting Propylex?

Official drug information notes that tiredness or fatigue can occur as a symptom of Hypothyroidism, a state of low thyroid hormones that can be caused by the medication. Additionally, drowsiness is listed as a potential side effect in regulatory documents.


Q: Does Propylex cause weight changes?

Regulatory sources document that weight gain is a possible symptom of Hypothyroidism (low thyroid hormone levels). Since Propylex works to lower thyroid hormone production, this change in hormone balance can be associated with weight changes.


Q: Do I need to stop taking Propylex suddenly?

Regulatory documents describe scenarios where the medication must be discontinued immediately. This action is required if a patient shows signs of a severe adverse reaction, such as a high fever, sore throat (potential sign of agranulocytosis), or jaundice (sign of liver damage). The regulatory warning mandates contacting a physician for immediate evaluation and testing in these situations.


Q: Is Propylex considered safe for long-term use?

Propylex is typically taken over a long treatment course, often lasting 12 to 18 months or more. However, official labeling warns that a condition called ANCA-associated vasculitis, a serious blood vessel inflammation, has been associated with prolonged use of Propylthiouracil.


Q: Can I take Propylex if I am on medication for blood pressure?

Official regulatory documents state that Propylthiouracil can interact with medicines used for high blood pressure and heart problems. Official labeling requires that all medications, including these, be disclosed to the prescribing professional to ensure proper review for interactions.


Q: Is there a generic version of Propylex?

Yes, the active ingredient in Propylex, which is Propylthiouracil, is documented as having generic availability in the US.


Q: Why do some people say Propylex helps with symptoms other than its main use?

The official uses for this medication are strictly confined by regulatory agencies to treating conditions like Graves' disease with hyperthyroidism or toxic multinodular goiter in specific patients. Information regarding other uses is not documented in the regulatory label.


Q: What is the difference between Propylex and similar drugs in the same class?

Propylthiouracil is distinct from similar antithyroid medications because it uniquely inhibits the peripheral conversion of the less active thyroid hormone (T4) into the highly active form (T3). This is in addition to its primary function of reducing hormone production in the thyroid gland.


Q: Does Propylex affect sleep patterns?

Official drug information lists drowsiness (sleepiness) as a potential adverse reaction. If this occurs, it may affect alertness and sleep patterns.


Q: Is it normal to have a slight headache when adjusting to Propylex?

Official adverse reaction reporting documents list headache as a common or minor reaction associated with Propylthiouracil.


Q: Is Propylex known to interact with herbal supplements like St. John's Wort?

Official prescribing information requires that all herbal supplements be disclosed to the prescribing professional. This ensures they can be reviewed for any potential impact on the medication's effectiveness or safety profile.


Q: Does Propylex need a special warning label?

Yes, Propylthiouracil is subject to a Boxed Warning (often called a Black Box Warning) in the US. This is the strictest warning required by the FDA and concerns the risk of severe liver injury and acute liver failure.


Q: Is Propylex a daily medication or is it taken as needed?

According to official product information, Propylex is typically taken as a fixed, daily regimen for a long period. This fixed schedule often involves multiple administrations throughout the day to maintain a consistent therapeutic action, rather than being taken only as needed.


Q: Are there any known long-term side effects of Propylex?

Serious reactions have a time-related pattern. The risk of ANCA-associated vasculitis has been reported with prolonged use. In contrast, severe liver problems are more frequently reported within the first six months of therapy.


Q: Is Propylex metabolized by the liver?

Yes, regulatory data indicates that Propylthiouracil is extensively metabolized (broken down) in the liver (hepatic metabolism). This extensive metabolism is a primary factor in the drug's potential for hepatotoxicity (liver damage).


Q: Does Propylex have any warnings related to driving or operating machinery?

Official warnings indicate that the medication may impair reactions due to the potential for side effects like dizziness and drowsiness. For this reason, caution is required when driving or operating machinery until the patient knows how the medication affects them.


Q: What should I do if I think Propylex is not working?

Regulatory documents note that it may take some time before the full benefit of the medicine is observed. However, in cases where severe illness is suspected (such as fever or sore throat), the regulatory advice is that the medication be discontinued immediately and a physician consulted for evaluation.


Q: Can I use Propylex if I have a history of heart issues?

Official medication guides state that a history of heart problems must be disclosed to the prescribing professional. Caution is also advised when the drug is used in older patients due to the greater frequency of decreased cardiac function in that population.


Q: What kind of monitoring is typically done while taking Propylex?

Periodic monitoring of thyroid function tests (e.g., TSH and Free T4) is necessary to check hormone levels. Monitoring of prothrombin time (a measure of blood clotting) should also be considered, particularly before surgical procedures.


Q: What are the most common reasons why Propylex is stopped?

The medication is discontinued immediately if a patient shows signs of severe adverse reactions, which include agranulocytosis (a serious blood disorder), hepatitis (liver inflammation), or ANCA-positive vasculitis.


Q: Is the research evidence for Propylex considered strong?

The research base for Propylex includes Randomized Controlled Trials (RCTs) and Systematic Reviews. The studies typically examined objective measures, such as thyroid hormone biomarkers. Findings regarding long-term remission durability have been mixed across trials.


Q: What is the relationship between Propylex and alcohol consumption?

Propylex carries a documented risk of hepatotoxicity (liver damage). Official documentation notes that alcohol use is a documented risk factor for hepatitis, which may necessitate monitoring for patients taking this medication.

How should Propylex be stored and disposed of?

How to Store and Dispose of Propylex (Propylthiouracil)

Propylex (Propylthiouracil) tablets must be stored according to specific regulatory requirements to maintain product stability.

Official Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature (15 C to 30 C) and keep from freezing
Protection Keep away from excess heat, moisture, and direct light
Container Rule Keep in the original container and ensure it is tightly closed
Child Safety Must be stored out of the reach and sight of children

Disposal Instructions

Do not keep outdated medicine. Unused or expired Propylthiouracil should be disposed of safely through a designated drug take-back program. If a take-back program is unavailable, follow the officially recommended household disposal procedure by mixing the tablets with an undesirable substance and placing them in a sealed container before disposal in the trash. The medication is not recommended for flushing down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Propylex found in:

A-Z Index: